Diego A. Díaz García: Immune Checkpoint Inhibitors May Extend Survival in EGFR-TKI–resistant NSCLC
Diego A. Díaz García, Medical Oncologist / CEO / Founder at CánCare – Advanced Specialty in Oncology, shared a post on LinkedIn:
“Immune checkpoint inhibitors may extend survival in EGFR-TKI–resistant NSCLC.
A meta-analysis of eight randomized trials including 2,269 patients with advanced EGFR-mutant NSCLC resistant to EGFR-TKIs found that adding immune checkpoint inhibitors (ICIs) to chemotherapy with or without antiangiogenic agents significantly improved outcomes compared with chemotherapy/antiangiogenic therapy alone.
Median progression-free survival improved by 33% (HR 0.67, p<0.001), overall survival by 11% (HR 0.89, p=0.031), and objective response rate by 20% (RR 0.80, p<0.001). Benefits were most pronounced in patients with PD-L1 expression ≥50%, Leu858Arg mutations, absence of Thr790Met, and those treated with pemetrexed-platinum.
No significant increase in grade ≥3 adverse events was observed, although discontinuations and specific toxicities such as rash, hypothyroidism, and hypertension were more frequent with ICI combinations.
JCO Precision Oncology.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023